Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome (3 4 DAP)
Expanded access is currently available for this treatment.
Verified April 2013 by The Cleveland Clinic
Sponsor:
The Cleveland Clinic
Information provided by (Responsible Party):
The Cleveland Clinic
ClinicalTrials.gov Identifier:
NCT01373333
First received: June 13, 2011
Last updated: April 17, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | Expanded access is currently available for this treatment. |
|---|---|
| Estimated Study Completion Date: | No date given |
| Estimated Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |